Health
Platform to predict future AF/atrial flutter nets breakthrough device designation – Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter,…
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected] to Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter, developed in collaboration with Geisinger.
The platform (Tempus ECG Analysis Platform, Tempus and Geisinger) is designated for use in patients aged 40 years and older who do not…
-
Business23 hours agoForget CBA and buy these high-yield ASX dividend shares
-
General23 hours agoWhy do states and territories have different school holidays?
-
Business24 hours agoHere’s a starter portfolio of ASX 200 shares to consider for growth, dividends, and value!
-
Noosa News20 hours agoMan dies after stabbing in inner-city unit